McKesson Corporation (MCK)

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors looking at 2026. AbbVie is transitioning its focus to newer immunology drugs, while Pfizer is pursuing aggressive acquisitions in oncology and metabolic assets to counter post-pandemic revenue declines and upcoming patent expirations. While both offer significant dividends, Pfizer appears to be the more undervalued stock based on current valuation metrics, despite AbbVie's promising pipeline.

Sep 25, 2026

This article compares AbbVie and Pfizer, two pharmaceutical giants, for investors in 2026, analyzing their financial performance, product pipelines, and risk profiles. While AbbVie is transitioning from its Humira era with new immunology leaders, Pfizer is focusing on oncology and metabolic assets through acquisitions, navigating post-pandemic changes and patent expirations. The author ultimately suggests Pfizer is currently undervalued despite AbbVie's promising pipeline, due to Pfizer's lower valuation metrics and recent growth in its oncology business.

Sep 25, 2026

McKesson (MCK) recently raised its full-year adjusted EPS guidance, leading to investor reassessment despite a recent share price dip. While the stock has seen strong long-term gains, short-term momentum has cooled, prompting questions about its current valuation. Analysts, based on a "most followed view," suggest McKesson is still 11% undervalued, with a fair value of $980.73, driven by its focus on oncology and access platforms.

Sep 25, 2026

Henry Schein, Inc. (HSIC) is outperforming the Dow Jones Industrials Average ($DOWI) year-to-date and over the past 52 weeks, driven by strong internal sales, dental merchandise gains, and strategic acquisitions. The company's Q2 results exceeded Wall Street expectations for both EPS and revenue, contributing to a "Moderate Buy" rating from analysts. HSIC continues to focus on digital transformation and long-term growth through its BOLD+1 plan and investments in technology.

Sep 24, 2026

This article compares Cardinal Health (CAH) and McKesson (MCK), two major players in U.S. pharmaceutical distribution. While both are positioned for growth and leverage specialty pharmaceuticals and technology, Cardinal Health shows stronger earnings momentum, better valuation, and a more favorable estimate revision trend. McKesson, despite its scale and specialty services, exhibits less valuation differentiation and a weaker momentum score.

Sep 24, 2026

The article compares Cardinal Health (CAH) and McKesson (MCK), two direct competitors in U.S. pharmaceutical distribution, evaluating their recent performance, growth strategies, and valuation. It concludes that while both are strong companies, CAH currently presents a more compelling investment due to its stronger projected EPS growth, favorable valuation, and estimate momentum, despite both holding a Zacks Rank #3 (Hold).

Sep 23, 2026

McKesson has confirmed that data theft from its August cyberattack is limited to certain third-party applications serving its Oncology & Multispecialty business, affecting patients at cancer centers and specialty practices. The company will notify affected individuals, but has found no indication that its drug distribution business or CoverMyMeds were impacted. While specific details on the number of affected individuals and practices are still emerging, the company advises caution with unexpected communications and suggests monitoring insurance statements.

Sep 21, 2026

Shares of McKesson Corp. (MCK) rose 1.35% on Monday, closing at $886.47. Despite the gain, the stock underperformed the broader market, as the S&P 500 Index increased by 1.49% and the Dow Jones Industrial Average rose by 0.71%. This rise ended a four-day losing streak for McKesson.

Sep 19, 2026

Cardinal Health (NYSE:CAH) projects a 13-15% adjusted EPS growth for fiscal year 2027, primarily driven by operating income growth across its business segments, and reiterates a longer-term EPS growth target of 12-14%. Specialty services, including oncology, urology, and autoimmune care, are anticipated to be a key growth engine, with BioPharma Solutions aiming for $1 billion in revenue by fiscal 2028. The company also plans $1 billion in share repurchases and expects contributions from at-home solutions and recent acquisitions, while managing the recovery of its medical-products division.

Sep 18, 2026

This article compares AbbVie (NYSE:ABBV) and Bristol Myers Squibb (NYSE:BMY) as potential healthcare stock investments for 2026, weighing their financial performance, growth strategies, and risk profiles. While Bristol Myers Squibb appears cheaper based on valuation metrics, AbbVie is recommended due to its successful navigation of patent cliffs and strong immunology and neuroscience pipeline, making it a more predictable choice for patient investors.

Sep 17, 2026

This article compares Amgen and Vertex Pharmaceuticals to determine which healthcare stock is a better investment in 2026. While Amgen offers stability and a diversified portfolio, Vertex Pharmaceuticals is highlighted for its high-growth potential, dominant position in cystic fibrosis, expanding pipeline, and superior operating margins. The author ultimately recommends Vertex for long-term investors seeking growth in the healthcare sector.

Sep 16, 2026

McKesson (MCK) experienced a 1.36% dip, underperforming the broader market. Despite this, the stock has gained 3.49% over the past month. Analysts project a 9.03% increase in EPS for the upcoming earnings report and significant growth for the full year, indicating a positive outlook from recent estimate revisions.

Sep 15, 2026

McKesson (NYSE: MCK) has significantly outperformed the market over the last five years, with an annualized return of 34.83%. An initial investment of $100 in MCK stock five years ago would now be worth $433.00, demonstrating the power of compounded returns. The company currently has a market capitalization of $104.88 billion.

Sep 15, 2026

McKesson Corp. (MCK) shares fell 1.25% to $899.56 on Tuesday, breaking a two-day winning streak. Despite this, the stock outperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average also experienced losses.

Sep 14, 2026

McKesson Corp (MCK) shares rose 3.3% to $910.95, a 28.6% increase over the past year, but GuruFocus assesses the stock as 9.8% overvalued with a GF Value™ of $829.63. Despite a strong GF Score™ of 80/100, indicating solid profitability and growth, significant insider selling of $28.3 million with no buying raises a cautionary flag for potential investors.